Abstract 9675: Does the Degree of Left Ventricular Dysfunction or Symptom Status Influence the Risk of Stroke or Systemic Embolism Among Patients With Atrial Fibrillation and Heart Failure?-Results From the ACTIVE Study
Background: Heart failure (HF) is a major component of widely applied stroke risk stratification schemes in atrial fibrillation (AF). However, data regarding the relationship between left ventricular (LV) dysfunction or HF symptoms and risk of stroke/systemic embolism among HF patients remains sparse.
Methods: A total of 3487 participants from the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE) trials with HF at baseline were randomized to anti-platelet therapy. Patients with HF were categorized as having preserved vs reduced ejection fraction (PEF ≥ 0.50, REF < 0.50). If reduced, the degree of LV dysfunction was classified as mild, moderate or severe. HF symptoms were assessed using New York Heart Association (NYHA) class I-IV. Cox proportional-hazards models were used to estimate hazard ratios (HR, 95% CI) for stroke/systemic embolism across categories of LV dysfunction and NYHA class.
Results: At baseline, 875 (47%) had HF-PEF, 982 (53%) had HF-REF; the degree of LV dysfunction was classified as mild in 25%, moderate in 25% and severe in 14%. During 3.6 years of follow-up, 211 patients had stroke/systemic embolism. In multivariable analysis, independent predictors of stroke were age ≥ 75 years (HR 2.83, 1.80-4.44), diabetes (HR 1.45, 1.03-2.03), diastolic blood pressure (per 1 mmHg, HR 1.02, 1.01-1.04), peripheral arterial disease(HR 1.94, 1.10-3.41), female(HR 1.48, 1.07-2.05) and prior stroke/transient ischemic attack (HR 1.77, 1.23-2.54) however EF < 0.50, LV dysfunction or NYHA class were not predictors. Compared to those with HF-REF, patients with HF-PEF exhibited similar risk of stroke/systemic embolism: 4.18% vs. 3.83% per year, HR 0.89, 95% CI 0.65-1.22 after controlling for AF risk factors. Compared to normal LV function, there was no significant trend across categories of LV systolic dysfunction (p for trend, 0.57). The risk of stroke/systemic embolism was similar in HF patients with NYHA class I (4.0% per year, referent category), II (4.0%, HR 0.87, 0.60-1.26), III (3.9%, HR 0.62, 0.38-1.02), or IV (2.8%, 0.60, 0.14-2.55).
Conclusion: Among patients with a history of HF, the presence or absence of LV dysfunction or severity of HF symptoms did not influence the risk of stroke/systemic embolism.
- © 2013 by American Heart Association, Inc.